Vivos reports positive initial RadioGel clinical trial results; plans expansion to 50 patients

VIVOS INC

First 5 patients showed safety; Y-90 remained at injection site with no adverse events.
One patient (cancerous node near trachea) showed over 80% reduction in tumor size and metastatic activity.
Lead investigator to request Ethics Committee approval to expand trial from 30 to 50 patients.
New deep-injection CT-guided device targets deeper tumors (lung, pancreatic); initial trial by June 30, expanded by year-end.
Data to be published and shared with FDA to support IDE submission for expanded U.S. indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.